.jetcityimage/iStock Content through Getty Images Morgan Stanley has opted for Eli Lilly (NYSE: LLY) as its own best biopharma pick for 2025 and also rated an additional 9 labels in the area as over weight. The investment financial institution mentioned in a details that it remains to feel “diabesity is readied to become.